Immunomic, Astellas deal

Immunomic granted Astellas exclusive, Japanese rights to develop and commercialize JRC2-LAMP-vax vaccine and an exclusive option to negotiate a license for other LAMP-vax DNA vaccines. Immunomic will conduct Japanese preclinical development, and the pharma will fund preclinical development and be responsible for clinical development. Immunomic retains rights outside of Japan. Immunomic will receive $15 million up front and is eligible for $55 million in development and regulatory milestones as well as technology transfer payments, plus tiered double-digit royalties. ...